This cluster is too small to warrant a trading signal. Monitor for any C-suite open-market sales exceeding 0.1% of market cap, which would carry more weight. The next catalyst is likely the Q2 2026 earnings release.
EXEL drugs
EXEL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 4 $52.39entry
- T+1 · 5mo ago +0.57%α +3.17% · $52.69
- T+5 · 5mo ago +2.12%α +4.68% · $53.50
- T+20 · 4mo ago +6.61%α +8.23% · $55.85
- T+60 · 3mo ago +3.84%α +2.22% · $54.40
Price Chart
How similar events traded
Executive Summary
Two Exelixis directors sold a total of ~$690K in open-market transactions over a 7-day window, representing ~0.006% of the company's $12.2B market cap. The dollar value is trivial relative to company size, and the trades lack C-suite participation, making this a routine cluster with no material signal.
Key Financial Metrics
Key Facts
- Two directors sold a combined 13,737 shares for ~$690K in open-market transactions.
- Total cluster value is ~0.006% of Exelixis' $12.2B market cap.
- No C-suite executives (CEO, CFO, etc.) participated in the cluster.
- The cluster includes no open-market purchases, all transactions are sales.
Financial Impact
~$690K in total insider sales, immaterial relative to $12.2B market cap.
Risk Factors
- Insider sales could accelerate if upcoming earnings disappoint, but current volume is negligible.
- No immediate risk from this cluster given the trivial dollar amounts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-EXEL-1780527146591 |
Track record
16 reports on EXEL
0 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +21.97% at T+60 after the Feb 28, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20266d ago SC 13G Neutral 3/10 Entry $70.58 to $70.70 Now $67.10 −4.93% ▲ +0.17% −1.15% vs SPY
- Nov 9, 20266d ago SC 13D/A Bearish 5/10 Entry $70.58 to $70.70 Now $67.10 +4.93% ▼ −0.17% +1.15% vs SPY
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $69.39 to $70.13 Now $67.10 −3.30% ▲ +1.07% +1.55% vs SPY
- Oct 20, 202627d ago Institutional Cluster Neutral 2/10 Entry $64.58 to $65.31 Now $67.10 +3.90% ▲ +1.13% +2.31% vs SPY
- Oct 12, 20265w ago Institutional Cluster Neutral 3/10 Entry $59.82 to $59.51 Now $67.10 +12.17% ▼ −0.52% −0.51% vs SPY
- Sep 11, 20269w ago 8-K Bearish 6/10 Entry $56.12 to $56.21 Now $67.10 −19.57% ▼ −0.16% −0.61% vs SPY
- Jun 3, 202623w ago Insider Cluster Neutral 2/10 Viewing Entry $52.39 to $52.69 Now $67.10 +28.08% ▲ +0.57% +3.17% vs SPY
- May 29, 202624w ago 8-K Neutral 3/10 Entry $50.20 to $48.49 Now $67.10 +33.67% ▼ −3.41% −3.55% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers